Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost.

Next Previous
X
Search
Trial Profile

A phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV DNA vaccine (Primary) ; NYVAC-C (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 16 Feb 2010 Interim results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
    • 17 Dec 2009 Planned number of patients changed from 140 to 147 as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top